85666-17-7
中文名称
U-63557A
英文名称
U-63557A
CAS
85666-17-7
分子式
C15H10NNaO3
分子量
275.23
MOL 文件
85666-17-7.mol
更新日期
2024/08/25 23:31:25
![85666-17-7 结构式](/CAS/GIF/85666-17-7.gif)
基本信息
中文别名
化合物 T11339化合物FUREGRELATE SODIUM
英文别名
U-63557Afuregralate sodium
SODIUM FUREGRELATE
FUREGRELATE SODIUM
FUREGRELATE SODIUM SALT
Furegrelate Sodium (U-63557A)
Sodium 5-(3-pyridinylmethyl)-2-benzofurancarboxylate
5-(3'-Pyridinylmethyl)benzofuran-2-carboxylate sodium
sodium:5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate
5-(3-Pyridylmethyl)benzofuran-2-carboxylic acid sodium salt
物理化学性质
储存条件−20°C
溶解度DMF: >25 mg/ml; DMSO: >21 mg/ml; Ethanol: >14.5 mg/ml; PBS pH 7.2: >16.5 mg/ml
形态白色至类白色结晶固体。
颜色White to light yellow
水溶解性Soluble in water at approximately 15mg/ml
常见问题列表
生物活性
Furegrelate Sodium (U-63557A) 是一种有效的、口服的、选择性的血栓素合酶 (thromboxane synthase) 抑制剂。Furegrelate Sodium 抑制人血小板微粒体血栓素 A2 (TxA2) 合酶,其 IC50 为 15 nM。Furegrelate Sodium 正在开发作为抗血小板药物。体内研究
Furegrelate Sodium (U-63557A) (1-5 mg/kg; Oral) prevents blockage of the coronary artery.
Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation.
Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.
Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme.
Animal Model: | Mongrel dogs (19-30 kg) |
Dosage: | 1-5 mg/kg |
Administration: | Oral (via a gastric tube) |
Result: | Prevented blockage of the coronary artery. |